<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PCOMPBIOL-D-11-00308</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1002213</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Probability theory</subject>
            <subj-group>
              <subject>Stochastic processes</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Oncology</subject>
            <subj-group>
              <subject>Cancer detection and diagnosis</subject>
              <subject>Cancer prevention</subject>
              <subject>Cancers and neoplasms</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Oncology</subject>
          <subject>Mathematics</subject>
        </subj-group>
      </article-categories><title-group><article-title>Number and Size Distribution of Colorectal Adenomas under the Multistage Clonal Expansion Model of Cancer</article-title><alt-title alt-title-type="running-head">Number and Sizes of Colorectal Adenomas</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dewanji</surname>
            <given-names>Anup</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Jeon</surname>
            <given-names>Jihyoun</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Meza</surname>
            <given-names>Rafael</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Luebeck</surname>
            <given-names>E. Georg</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Applied Statistics Division, Indian Statistical Institute, Kolkata, India</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Program in Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>Program in Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Kimmel</surname>
            <given-names>Marek</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Rice University, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">gluebeck@fhcrc.org</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: AD JJ RM EGL. Analyzed the data: JJ EGL. Contributed reagents/materials/analysis tools: AD JJ. Wrote the paper: AD EGL. Drafted the paper: AD EGL. Revised the paper: JJ RM EGL.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>10</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>13</day>
        <month>10</month>
        <year>2011</year>
      </pub-date><volume>7</volume><issue>10</issue><elocation-id>e1002213</elocation-id><history>
        <date date-type="received">
          <day>7</day>
          <month>3</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>8</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Dewanji et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <p>Colorectal cancer (CRC) is believed to arise from mutant stem cells in colonic crypts that undergo a well-characterized progression involving benign adenoma, the precursor to invasive carcinoma. Although a number of (epi)genetic events have been identified as drivers of this process, little is known about the dynamics involved in the stage-wise progression from the first appearance of an adenoma to its ultimate conversion to malignant cancer. By the time adenomas become endoscopically detectable (i.e., are in the range of 1–2 mm in diameter), adenomas are already comprised of hundreds of thousands of cells and may have been in existence for several years if not decades. Thus, a large fraction of adenomas may actually remain undetected during endoscopic screening and, at least in principle, could give rise to cancer before they are detected. It is therefore of importance to establish what fraction of adenomas is detectable, both as a function of when the colon is screened for neoplasia and as a function of the achievable detection limit. To this end, we have derived mathematical expressions for the detectable adenoma number and size distributions based on a recently developed stochastic model of CRC. Our results and illustrations using these expressions suggest (1) that screening efficacy is critically dependent on the detection threshold and implicit knowledge of the relevant stem cell fraction in adenomas, (2) that a large fraction of non-extinct adenomas remains likely undetected assuming plausible detection thresholds and cell division rates, and (3), under a realistic description of adenoma initiation, growth and progression to CRC, the empirical prevalence of adenomas is likely inflated with lesions that are not on the pathway to cancer.</p>
      </abstract><abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>The adenomatous polyp (or adenoma) is considered the common precursor lesion for colorectal cancer (CRC). Although the natural history of adenomas is well-characterized in terms of their histopathology and (epi)genomic changes, little is known about their dynamics in the stage-wise progression from the first appearance of an adenoma to its conversion to malignant cancer. By the time adenomas become endoscopically detectable (i.e., are in the range of 1–2 mm in diameter), adenomas are already comprised of hundreds of thousands of cells. A large fraction of adenomas may therefore remain undetected during screening and, in spite of their small (subthreshold) size, could give rise to cancer prior to being detected. It is therefore of importance to establish what fraction of adenomas is detectable, both as a function of the age at screening for colorectal neoplasia and the size (threshold) above which adenomas can be detected reliably. Here we derive mathematical expressions for the distribution of adenoma number and sizes based on a recently developed stochastic model for CRC, which has previously been calibrated and validated against age-specific CRC incidence data.</p>
      </abstract><funding-group><funding-statement>This work was supported by National Institutes of Health Grant RO1 CA107028-05A1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="10"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Adenomatous polyps (or adenomas) in the large intestine are considered benign precursors of colorectal cancer (CRC) and both clinical and molecular evidence suggest that they may sojourn for many years before turning into cancer <xref ref-type="bibr" rid="pcbi.1002213-Winawer1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Jones1">[2]</xref>. For this reason, adenomas are considered a primary intervention target if detected and removed before they become malignant. However, questions remain regarding the significance of their histopathology, molecular signatures, as well as their number and sizes in average risk individuals. Since endoscopic screening for neoplastic lesions is generally limited by macroscopic detection thresholds (of the order of a few mm in caliper size), a large fraction of adenomas may actually be missed, especially if the bulk of adenomas is too small for detection. Potentially, such “occult” adenomas could give rise to cancer before they are detected by endoscopy. Here we use a biologically-based model of colorectal carcinogenesis, which has previously been fitted to the age-specific incidence of CRC, to compute the number and size distributions of adenomas. Of particular interest is the fraction of detectable adenomas, as functions of age, detection threshold and the underlying cell kinetics in the adenomas.</p>
      <p>The underlying multistage clonal expansion (MSCE) model for CRC upon which our results are based explicitly considers the initiation, promotion and malignant conversion of adenomas <xref ref-type="bibr" rid="pcbi.1002213-Luebeck1">[3]</xref>–<xref ref-type="bibr" rid="pcbi.1002213-Meza3">[8]</xref>. According to this model, adenomas arise from normal colonic stem cells that suffer at least two rare rate-limiting events. We interpret these events as the biallelic inactivation of a tumor suppressor gene, in particular the APC tumor suppressor gene, which is the gene responsible for familial adenomatous polyposis (FAP), and which is frequently mutated in colorectal neoplasia <xref ref-type="bibr" rid="pcbi.1002213-Goss1">[9]</xref>. The inactivation of APC is understood to occur in colonic crypts (the fundamental proliferative unit in the colon) whose stem cells have previously acquired a mutation at one of the two APC alleles. Because the process of adenoma formation may involve additional genes (such as KRAS), we extend the model framework to accommodate additional rate-limiting mutations for the initiation of an adenoma and generalize the mathematical derivation of their number and size distribution accordingly. However, there is both clinical and experimental evidence that the number of requisite rate-limiting events or mutations for adenoma initiation is small. Once a stem cell is initiated in this model, it is free to proliferate. The basic version of our CRC model assumes that adenoma initiation occurs when the remaining wild-type copy of the APC tumor suppressor gene is deleted or mutated in a stem cell of a (pre-initiated) APC+/− colonic crypt. In a more realistic model, which is supported by recent experimental findings in the murine system <xref ref-type="bibr" rid="pcbi.1002213-Barker1">[10]</xref>, we also model the transient amplification of APC−/− stem cells prior to their clonal expansion, effectively adding a stage to the initiation process <xref ref-type="bibr" rid="pcbi.1002213-Barker1">[10]</xref>–<xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref>.</p>
      <p>The theoretical results derived here are complemented by model predictions for the adenoma size distributions and their (age-specific) prevalence based on parameter estimates obtained previously from fitting cancer incidence data. Since not all biological model parameters can be directly estimated from incidence data alone (non-identifiability issue), we explore the sensitivity of our findings by varying unknown parameters, such as the cell division rate of initiated stem cells, within their plausible ranges. In spite of the model uncertainties and the lack of precise clinical data on adenoma number and sizes, a biologically based approach that is broadly consistent with the pathogenesis of CRC makes it possible to explore more rationally the impact of risk factors and interventions on adenoma development and cancer progression.</p>
    </sec>
    <sec id="s2">
      <title>Model</title>
      <sec id="s2a">
        <title>The Multistage Clonal Expansion (MSCE) Model</title>
        <p>First we briefly review the MSCE model for CRC and then introduce the notation for the relevant stochastic processes involved in the formation of adenomas. We have previously derived expressions for the number and size distribution of non-extinct pre-malignant clones in the context of the two-stage clonal expansion (TSCE) model <xref ref-type="bibr" rid="pcbi.1002213-Dewanji1">[13]</xref>. This model assumes that the clones develop from a (deterministic) source of progenitor cells via a non-homogeneous Poisson process. An important extension of this work was put forward by Dewanji et al. <xref ref-type="bibr" rid="pcbi.1002213-Dewanji2">[14]</xref> for the size distribution of a random sum of Poisson-generated (pre-malignant) clones, which corresponds to a generalized Luria-Delbrück (GLD) distribution for mutant colonies. A hallmark of this distribution is a long tail reflecting large fluctuations of the total (mutant) population size. A further extension derived expressions for the number and size distributions of pre-malignant clones conditioning on observations from individuals who have not previously been diagnosed with CRC <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>.</p>
        <sec id="s2a1">
          <title>Adenoma development</title>
          <p>For colorectal adenomas, the MSCE model assumes that adenomas arise within colonic crypts maintained by immortal stem cells that have accumulated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e001" xlink:type="simple"/></inline-formula> requisite (epi)genetic pre-initiation events. In this model, adenomas are allowed to be multi-focal since the initiation process, starting from the time when the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e002" xlink:type="simple"/></inline-formula>th pre-initiation event has occurred in a stem cell, is a point process representing the continuous generation of initiated cells from the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e003" xlink:type="simple"/></inline-formula>-stage cell, the progeny of which is free to undergo clonal expansion. In this picture, pre-initiated stem cells are blocked from clonal expansion; however, they are allowed to divide asymmetrically to generate daughter cells that will (ultimately) undergo terminal differentiation (see <xref ref-type="fig" rid="pcbi-1002213-g001">Figure 1</xref>). This is described in more detail below. To give an example, for a 3-step initiation model (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e004" xlink:type="simple"/></inline-formula>), adenomas arise from crypts whose stem cell population sustains two consecutive hits (e.g., the inactivation of both alleles of the APC gene). In this case initiating events occur when the crypt stem cells suffer a third event.</p>
          <fig id="pcbi-1002213-g001" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pcbi.1002213.g001</object-id>
            <label>Figure 1</label>
            <caption>
              <title>Multistage clonal expansion (MSCE) model.</title>
              <p>SC: stem cell, D: differentiated cell.</p>
            </caption>
            <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.g001" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="s2a2">
          <title>Pre-initiation events</title>
          <p>There are two distinct biological ways for pre-initiation events to occur at the cellular level. A pre-initiation event may occur in a stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e005" xlink:type="simple"/></inline-formula> stem cell via an asymmetric stem cell division in which a mutation occurs in one of the two daughter stem cells. In other words, a stem cell in the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e006" xlink:type="simple"/></inline-formula>th pre-initiation stage may divide asymmetrically to yield two daughter stem cells, one in stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e007" xlink:type="simple"/></inline-formula> and the other in stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e008" xlink:type="simple"/></inline-formula> which acquires a new mutation (<xref ref-type="fig" rid="pcbi-1002213-g001">Figure 1A</xref>). This process is mathematically modeled as a Poisson process with intensity rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e009" xlink:type="simple"/></inline-formula>. In this case, both daughters are retained in the stem cell compartment. The other possibility is represented by another kind of asymmetric stem cell division which causes one daughter stem cell to acquire a mutation leading to a transition of this cell to stage (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e010" xlink:type="simple"/></inline-formula>), while the other daughter is committed to differentiation (<xref ref-type="fig" rid="pcbi-1002213-g001">Figure 1. B</xref>). For historical reasons, we refer to this event as an Armitage-Doll (AD) type transition <xref ref-type="bibr" rid="pcbi.1002213-Armitage1">[15]</xref>.</p>
          <p>For both cases we assume that a stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e011" xlink:type="simple"/></inline-formula> stem cell is not yet initiated and therefore lacks the potential for clonal expansion via symmetric cell divisions. However, once a stem cell enters stage (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e012" xlink:type="simple"/></inline-formula>), it is considered initiated and free to undergo clonal expansion. Furthermore, all stem cells in the pre-initiation stages are assumed immortal.</p>
        </sec>
        <sec id="s2a3">
          <title>Multi-focal nature of an adenoma</title>
          <p>In the context of the MSCE model for CRC, an adenoma consists of the collection of all initiated (stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e013" xlink:type="simple"/></inline-formula>) cells that derive from a <underline>single</underline> stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e014" xlink:type="simple"/></inline-formula> progenitor cell. This definition, while not unique, is consistent with the assumption that the stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e015" xlink:type="simple"/></inline-formula> progenitor may be subject to transient amplification, which is represented by frequent Poisson ‘emissions’ of initiated (stage <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e016" xlink:type="simple"/></inline-formula>) cells that are free to undergo independent clonal expansions resulting in the formation of multiple sub-clones (<xref ref-type="fig" rid="pcbi-1002213-g001">Figure 1C</xref>).</p>
          <p>We call this ensemble of sub-clones an <italic>adenoma</italic> or <italic>adenomatous polyp</italic>. Since information on adenoma number and sizes is typically obtained via screening of individuals who have not previously been diagnosed with CRC, we will also derive the results of the model conditioning on no prior clinical detection of CRC. For this purpose, we assume that the last rate-limiting event (with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e017" xlink:type="simple"/></inline-formula>) in the MSCE model, which is usually associated with the malignant conversion of an initiated cell, represents detection of a clinical cancer as in Jeon et al. <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>.</p>
        </sec>
        <sec id="s2a4">
          <title>Basic notation</title>
          <p>Suppose there are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e018" xlink:type="simple"/></inline-formula> pre-initiation stages. We refer to the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e019" xlink:type="simple"/></inline-formula>th pre-initiation event as a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e020" xlink:type="simple"/></inline-formula>-mutation and the cells, which have gone through this <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e021" xlink:type="simple"/></inline-formula>-mutation, as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e022" xlink:type="simple"/></inline-formula>-cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e023" xlink:type="simple"/></inline-formula>). For completeness, we refer to the normal stem cells as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e024" xlink:type="simple"/></inline-formula>-cells. The generation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e025" xlink:type="simple"/></inline-formula>-cells from one <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e026" xlink:type="simple"/></inline-formula>-cell can be modeled through a non-homogeneous PP with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e027" xlink:type="simple"/></inline-formula> per cell. Alternatively, it can be modeled as a direct transition of a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e028" xlink:type="simple"/></inline-formula>-cell into a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e029" xlink:type="simple"/></inline-formula>-cell, the AD-type transition referred to above, with hazard rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e030" xlink:type="simple"/></inline-formula> and density <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e031" xlink:type="simple"/></inline-formula> for the waiting time of a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e032" xlink:type="simple"/></inline-formula>-cell before the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e033" xlink:type="simple"/></inline-formula>-mutation takes place. For the AD type transition, it is assumed that the functions <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e034" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e035" xlink:type="simple"/></inline-formula> depend only on the time since the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e036" xlink:type="simple"/></inline-formula>-mutation occurred. If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e037" xlink:type="simple"/></inline-formula> is a constant, then <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e038" xlink:type="simple"/></inline-formula> is the density of an exponential distribution. Once a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e039" xlink:type="simple"/></inline-formula>-cell is formed (by means of a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e040" xlink:type="simple"/></inline-formula>-mutation), it generates initiated cells (i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e041" xlink:type="simple"/></inline-formula>-cells) according to a non-homogeneous PP with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e042" xlink:type="simple"/></inline-formula> and the initiated cells grow according to a linear birth and death process with rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e043" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e044" xlink:type="simple"/></inline-formula>, respectively. Note, the initiation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e045" xlink:type="simple"/></inline-formula>-cells and their clonal expansion recapitulates the two-stage clonal expansion (TSCE) model for which explicit solutions for the number and size distributions have been derived <xref ref-type="bibr" rid="pcbi.1002213-Dewanji1">[13]</xref>. <xref ref-type="fig" rid="pcbi-1002213-g001">Figure 1.C</xref> illustrates the MSCE model for carcinogenesis. The pre-initiation events can be either PP-type or AD-type transitions. However, the first step in the MSCE model represents the successive (random) generation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e046" xlink:type="simple"/></inline-formula> mutant stem cells over time and throughout the normal tissue, which is assumed to be very large in size - about <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e047" xlink:type="simple"/></inline-formula> normal stem cells in colon and rectum combined. Hence, without loss of generality, the MSCE model assumes that the arrivals of the first mutations are of the PP-type.</p>
        </sec>
        <sec id="s2a5">
          <title>Size and detection of an adenoma</title>
          <p>Suppose we observe, for an individual at a particular time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e048" xlink:type="simple"/></inline-formula>, the number of detectable adenomas, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e049" xlink:type="simple"/></inline-formula>, and their sizes (in terms of the number of initiated or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e050" xlink:type="simple"/></inline-formula>-cells in each adenoma), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e051" xlink:type="simple"/></inline-formula>. We assume that an adenoma is detectable with probability one if its size is greater than a fixed threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e052" xlink:type="simple"/></inline-formula>. In the following sections, we derive the joint distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e053" xlink:type="simple"/></inline-formula> for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e054" xlink:type="simple"/></inline-formula> and different assumptions regarding the type of pre-initiation process (i.e., PP or AD). For <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e055" xlink:type="simple"/></inline-formula>, we essentially consider the model recommended by Luebeck &amp; Moolgavkar <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref> for CRC and used by Jeon et al. <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref> for evaluating screening strategies for adenomas in colon and rectum. The latter study provided an efficient approach to simulate the natural history of CRC by recognizing that the size of the adenomas, given the arrival time of a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e056" xlink:type="simple"/></inline-formula>-cell, follows a GLD distribution as derived by Dewanji et al. <xref ref-type="bibr" rid="pcbi.1002213-Dewanji2">[14]</xref>.</p>
          <p>Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e057" xlink:type="simple"/></inline-formula> be the time of a particular <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e058" xlink:type="simple"/></inline-formula>-mutation, that is, the arrival time for a progenitor cell (a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e059" xlink:type="simple"/></inline-formula>cell) for an adenoma. Then this progenitor cell will generate initiated cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e060" xlink:type="simple"/></inline-formula>cells) by a Poisson process, and each initiated cell forms a sub-clone of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e061" xlink:type="simple"/></inline-formula>cells via a clonal expansion. Note, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e062" xlink:type="simple"/></inline-formula> is the (random) sum of all sub-clones of initiated cells (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e063" xlink:type="simple"/></inline-formula>cells) that were generated from the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e064" xlink:type="simple"/></inline-formula> progenitor stem cell which was born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e065" xlink:type="simple"/></inline-formula>.</p>
          <p>In particular, when the initiation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e066" xlink:type="simple"/></inline-formula>, the cell division rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e067" xlink:type="simple"/></inline-formula>, and the cell death rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e068" xlink:type="simple"/></inline-formula> are constants, the GLD distribution reduces to a Negative Binomial distribution (Eq. (3.34) in <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>), given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e069" xlink:type="simple"/><label>(1)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e070" xlink:type="simple"/></inline-formula> denotes the size of the adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e071" xlink:type="simple"/></inline-formula>, given the time of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e072" xlink:type="simple"/></inline-formula>-mutation <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e073" xlink:type="simple"/></inline-formula>, and<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e074" xlink:type="simple"/></disp-formula>Under these assumptions, the sub-clones that lead to this (multi-focal) distribution arise from initiated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e075" xlink:type="simple"/></inline-formula>-cells that expand clonally by following a linear birth-death process. For this reason, the results derived here are readily applied to the situation when the sub-clones are also identified clinically. Conditioning this distribution on adenomas that occur in cancer-free individuals, i.e., individuals who have not had a prior occurrence of CRC, we have (see Eq.(3.30) in <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>)<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e076" xlink:type="simple"/><label>(2)</label></disp-formula>where<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e077" xlink:type="simple"/><label>(3)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e078" xlink:type="simple"/><label>(4)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e079" xlink:type="simple"/><label>(5)</label></disp-formula>and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e080" xlink:type="simple"/></inline-formula> is the indicator variable for clinical detection of cancer at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e081" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e082" xlink:type="simple"/></inline-formula>-cells born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e083" xlink:type="simple"/></inline-formula>.</p>
        </sec>
      </sec>
      <sec id="s2b">
        <title>Number and Size Distribution for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e084" xlink:type="simple"/></inline-formula></title>
        <p>For <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e085" xlink:type="simple"/></inline-formula> we have only one pre-initiation event, defined by a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e086" xlink:type="simple"/></inline-formula>-mutation, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e087" xlink:type="simple"/></inline-formula>-cells are the initiated cells. As mentioned in the previous section, the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e088" xlink:type="simple"/></inline-formula>-mutation follows a PP formulation. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e089" xlink:type="simple"/></inline-formula> denote the size of the adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e090" xlink:type="simple"/></inline-formula> with the first pre-initiation (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e091" xlink:type="simple"/></inline-formula>-mutation) time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e092" xlink:type="simple"/></inline-formula>. The distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e093" xlink:type="simple"/></inline-formula> is given by the GLD distribution previously derived by Dewanji et al. <xref ref-type="bibr" rid="pcbi.1002213-Dewanji2">[14]</xref>, for the process originating at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e094" xlink:type="simple"/></inline-formula> and involving the initiation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e095" xlink:type="simple"/></inline-formula> and the birth and death rates of the initiated cells given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e096" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e097" xlink:type="simple"/></inline-formula>, respectively.</p>
        <p>As mentioned before, we assume that the generation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e098" xlink:type="simple"/></inline-formula>-cells follows a non-homogeneous PP with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e099" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e100" xlink:type="simple"/></inline-formula> gives the deterministic growth curve for the normal stem cells in the tissue. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e101" xlink:type="simple"/></inline-formula> be the number of first pre-initiations (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e102" xlink:type="simple"/></inline-formula>-mutations) by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e103" xlink:type="simple"/></inline-formula> and let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e104" xlink:type="simple"/></inline-formula> be the occurrence times of these <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e105" xlink:type="simple"/></inline-formula>-mutations. Also, write <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e106" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e107" xlink:type="simple"/></inline-formula> is the indicator function. That is, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e108" xlink:type="simple"/></inline-formula>, if the corresponding adenoma is detectable at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e109" xlink:type="simple"/></inline-formula>, and 0 otherwise. Then, the number of detectable adenoma <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e110" xlink:type="simple"/></inline-formula> can be written as a filtered Poisson process<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e111" xlink:type="simple"/></disp-formula>The probability generating function (PGF) of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e112" xlink:type="simple"/></inline-formula> can be written as<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e113" xlink:type="simple"/><label>(6)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e114" xlink:type="simple"/></inline-formula> is the PGF of the binary variate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e115" xlink:type="simple"/></inline-formula> with success probability<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e116" xlink:type="simple"/></disp-formula>Note that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e117" xlink:type="simple"/></inline-formula> is the probability that a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e118" xlink:type="simple"/></inline-formula>-mutation taking place at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e119" xlink:type="simple"/></inline-formula> results in a detectable adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e120" xlink:type="simple"/></inline-formula>. This probability can be obtained from the distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e121" xlink:type="simple"/></inline-formula>. For constant parameters, this reduces to, using (1) with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e122" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e123" xlink:type="simple"/></inline-formula>.</p>
        <sec id="s2b1">
          <title>Adenoma prevalence</title>
          <p>It follows that the number of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e124" xlink:type="simple"/></inline-formula>-cells which lead to detectable adenomas at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e125" xlink:type="simple"/></inline-formula> follows a non-homogeneous PP with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e126" xlink:type="simple"/></inline-formula>, with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e127" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e128" xlink:type="simple"/></inline-formula> has a Poisson distribution with mean <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e129" xlink:type="simple"/></inline-formula>. Since the adenoma prevalence is defined as the probability of at least one detectable adenoma at age t, it is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e130" xlink:type="simple"/><label>(7)</label></disp-formula></p>
        </sec>
        <sec id="s2b2">
          <title>Detection probability and size distribution of adenomas</title>
          <p>The probability of detecting an adenoma of size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e131" xlink:type="simple"/></inline-formula> at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e132" xlink:type="simple"/></inline-formula> is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e133" xlink:type="simple"/><label>(8)</label></disp-formula>For constant parameters, this reduces to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e134" xlink:type="simple"/></inline-formula>. Similarly, the size distribution of a detectable adenoma at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e135" xlink:type="simple"/></inline-formula> is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e136" xlink:type="simple"/><label>(9)</label></disp-formula></p>
        </sec>
        <sec id="s2b3">
          <title>Likelihood for the number and size of detectable adenomas</title>
          <p>Using the properties described above, it is straightforward to show that the joint probability (or likelihood <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e137" xlink:type="simple"/></inline-formula>) of having <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e138" xlink:type="simple"/></inline-formula> detectable adenomas with sizes <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e139" xlink:type="simple"/></inline-formula> at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e140" xlink:type="simple"/></inline-formula>, i.e, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e141" xlink:type="simple"/></inline-formula> is<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e142" xlink:type="simple"/><label>(10)</label></disp-formula></p>
        </sec>
        <sec id="s2b4">
          <title>Extension to observations in individuals with no prior CRC</title>
          <p>Here we derive analogous results for cancer-free individuals, i.e., individuals who have not developed CRC by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e143" xlink:type="simple"/></inline-formula>. To this end, we require the conditional probability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e144" xlink:type="simple"/></inline-formula> that a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e145" xlink:type="simple"/></inline-formula>-mutation taking place at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e146" xlink:type="simple"/></inline-formula>, results in a detectable adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e147" xlink:type="simple"/></inline-formula> prior to developing CRC. Hence, we need to compute the conditional probability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e148" xlink:type="simple"/></inline-formula>. For constant parameters, using (2), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e149" xlink:type="simple"/></inline-formula> can be calculated as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e150" xlink:type="simple"/></inline-formula>.</p>
        </sec>
        <sec id="s2b5">
          <title>Adenoma prevalence among individuals with no prior CRC</title>
          <p>As before, the number of detectable adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e151" xlink:type="simple"/></inline-formula> in a cancer-free individual, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e152" xlink:type="simple"/></inline-formula>, follows a Poisson distribution with mean given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e153" xlink:type="simple"/></inline-formula>, where the two-stage survival function <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e154" xlink:type="simple"/></inline-formula> represents the probability that a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e155" xlink:type="simple"/></inline-formula>-cell born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e156" xlink:type="simple"/></inline-formula> does not lead to CRC by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e157" xlink:type="simple"/></inline-formula>. Thus, the adenoma prevalence conditioned on cancer-free is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e158" xlink:type="simple"/><label>(11)</label></disp-formula></p>
          <p>For constant parameters, this two-stage survival function has been derived previously, i.e.<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e159" xlink:type="simple"/></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e160" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e161" xlink:type="simple"/></inline-formula> are defined in (4) and (5) with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e162" xlink:type="simple"/></inline-formula> (see <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref> for details).</p>
        </sec>
        <sec id="s2b6">
          <title>Detection probability, size distribution, and likelihood function for adenomas in individuals with no prior CRC</title>
          <p>Here we provide analogous expressions for the detection probability (8) and size distribution (9), but properly conditioned on no occurrence of prior CRC. The probability of detecting an adenoma at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e163" xlink:type="simple"/></inline-formula> with size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e164" xlink:type="simple"/></inline-formula>, conditioned on no prior CRC, can be written as<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e165" xlink:type="simple"/><label>(12)</label></disp-formula></p>
          <p>Similarly, for the size distribution of detectable adenomas (i.e., their sizes exceeding the threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e166" xlink:type="simple"/></inline-formula>) at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e167" xlink:type="simple"/></inline-formula>, conditioned on no prior CRC, we find<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e168" xlink:type="simple"/><label>(13)</label></disp-formula></p>
          <p>Finally, following the derivation of (10), the joint distribution of the number and sizes of detectable adenomas, in a cancer-free individual, can be written as<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e169" xlink:type="simple"/><label>(14)</label></disp-formula></p>
        </sec>
      </sec>
      <sec id="s2c">
        <title>Number and Size Distribution for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e170" xlink:type="simple"/></inline-formula></title>
        <p>Here the two pre-initiation events (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e171" xlink:type="simple"/></inline-formula>- and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e172" xlink:type="simple"/></inline-formula>-mutations) precede initiation and growth of initiated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e173" xlink:type="simple"/></inline-formula>-cells into sub-clones. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e174" xlink:type="simple"/></inline-formula> denote the size of the adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e175" xlink:type="simple"/></inline-formula> with the corresponding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e176" xlink:type="simple"/></inline-formula>- and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e177" xlink:type="simple"/></inline-formula>-mutations taking place at times <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e178" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e179" xlink:type="simple"/></inline-formula>, respectively. Note that the distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e180" xlink:type="simple"/></inline-formula> is given by the GLD distribution originating at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e181" xlink:type="simple"/></inline-formula> and involving the initiation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e182" xlink:type="simple"/></inline-formula> and the birth and death rates of the initiated or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e183" xlink:type="simple"/></inline-formula>-cells, given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e184" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e185" xlink:type="simple"/></inline-formula>, respectively. We derive explicit expressions for the number and size distributions for the case when both <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e186" xlink:type="simple"/></inline-formula>- and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e187" xlink:type="simple"/></inline-formula>-mutations are of PP-type. The case when the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e188" xlink:type="simple"/></inline-formula>-mutations are of AD-type is described in the online supplement (<xref ref-type="supplementary-material" rid="pcbi.1002213.s001">Text S1</xref>).</p>
        <p>As before, the number of detectable adenomas at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e189" xlink:type="simple"/></inline-formula> can be written as<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e190" xlink:type="simple"/><label>(15)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e191" xlink:type="simple"/></inline-formula> is the number of detectable adenomas that emerged from a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e192" xlink:type="simple"/></inline-formula>-cell born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e193" xlink:type="simple"/></inline-formula>. Then, as in (6), the PGF of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e194" xlink:type="simple"/></inline-formula> can be expressed by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e195" xlink:type="simple"/><label>(16)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e196" xlink:type="simple"/></inline-formula> is the PGF of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e197" xlink:type="simple"/></inline-formula>. Using the Lemma and eq. (10) of Dewanji et al. <xref ref-type="bibr" rid="pcbi.1002213-Dewanji2">[14]</xref>, we have further<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e198" xlink:type="simple"/><label>(17)</label></disp-formula>and for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e199" xlink:type="simple"/></inline-formula>,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e200" xlink:type="simple"/><label>(18)</label></disp-formula>where, for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e201" xlink:type="simple"/></inline-formula>.</p>
        <p>Again,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e202" xlink:type="simple"/><label>(19)</label></disp-formula>where this sum is over all the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e203" xlink:type="simple"/></inline-formula>-mutations by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e204" xlink:type="simple"/></inline-formula> that occurred at times <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e205" xlink:type="simple"/></inline-formula> and which emerged from a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e206" xlink:type="simple"/></inline-formula>-cell that was born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e207" xlink:type="simple"/></inline-formula>. Here, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e208" xlink:type="simple"/></inline-formula> if the adenoma originated from the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e209" xlink:type="simple"/></inline-formula>-cell born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e210" xlink:type="simple"/></inline-formula> and the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e211" xlink:type="simple"/></inline-formula>-cell born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e212" xlink:type="simple"/></inline-formula> is detectable at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e213" xlink:type="simple"/></inline-formula> and 0 otherwise; that is, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e214" xlink:type="simple"/></inline-formula>. Note that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e215" xlink:type="simple"/></inline-formula>, since <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e216" xlink:type="simple"/></inline-formula> does not depend on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e217" xlink:type="simple"/></inline-formula>. Therefore, as in the previous section, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e218" xlink:type="simple"/></inline-formula> is a filtered PP with the PGF <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e219" xlink:type="simple"/></inline-formula>, similar to that in (6). Also, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e220" xlink:type="simple"/></inline-formula> is a non-homogeneous PP with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e221" xlink:type="simple"/></inline-formula>, for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e222" xlink:type="simple"/></inline-formula>, and for fixed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e223" xlink:type="simple"/></inline-formula>, is a Poisson variate with mean <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e224" xlink:type="simple"/></inline-formula>, where<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e225" xlink:type="simple"/><label>(20)</label></disp-formula>This probability can be obtained from the distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e226" xlink:type="simple"/></inline-formula> given in (1).</p>
        <sec id="s2c1">
          <title>Adenoma prevalence</title>
          <p><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e227" xlink:type="simple"/></inline-formula> has the same form as that of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e228" xlink:type="simple"/></inline-formula> but with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e229" xlink:type="simple"/></inline-formula>. Thus, using (17), the adenoma prevalence is calculated by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e230" xlink:type="simple"/><label>(21)</label></disp-formula>The distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e231" xlink:type="simple"/></inline-formula> can now be obtained by using (18), and the expected number of detectable adenomas can be readily obtained using (16), i.e.<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e232" xlink:type="simple"/><label>(22)</label></disp-formula></p>
        </sec>
        <sec id="s2c2">
          <title>Detection probability and size distribution of adenomas</title>
          <p>The probability of detecting an adenoma of size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e233" xlink:type="simple"/></inline-formula> at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e234" xlink:type="simple"/></inline-formula> is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e235" xlink:type="simple"/><label>(23)</label></disp-formula></p>
          <p>For constant pre-initiation rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e236" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e237" xlink:type="simple"/></inline-formula>, and a constant normal stem cell number <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e238" xlink:type="simple"/></inline-formula>, this reduces to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e239" xlink:type="simple"/></inline-formula>. Similarly, the size distribution of a detectable adenoma at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e240" xlink:type="simple"/></inline-formula> is simply given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e241" xlink:type="simple"/><label>(24)</label></disp-formula></p>
        </sec>
        <sec id="s2c3">
          <title>Likelihood for the number and size of detectable adenomas</title>
          <p>Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e242" xlink:type="simple"/></inline-formula> be the number of ‘special’ <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e243" xlink:type="simple"/></inline-formula>-mutations that lead to at least one detectable adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e244" xlink:type="simple"/></inline-formula>. Because of the filtered-Poisson-process nature of the generation of the adenomas, the occurrence of such special <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e245" xlink:type="simple"/></inline-formula>-mutations follows a PP with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e246" xlink:type="simple"/></inline-formula>, for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e247" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e248" xlink:type="simple"/></inline-formula> is the probability that a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e249" xlink:type="simple"/></inline-formula>-mutation that occurred at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e250" xlink:type="simple"/></inline-formula> leads to at least one detectable adenoma by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e251" xlink:type="simple"/></inline-formula>. Using the distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e252" xlink:type="simple"/></inline-formula>, we have<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e253" xlink:type="simple"/><label>(25)</label></disp-formula></p>
          <p>We now turn to the joint distribution of having <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e254" xlink:type="simple"/></inline-formula> detectable adenomas with sizes <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e255" xlink:type="simple"/></inline-formula> at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e256" xlink:type="simple"/></inline-formula>, i.e, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e257" xlink:type="simple"/></inline-formula>, when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e258" xlink:type="simple"/></inline-formula>. First, let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e259" xlink:type="simple"/></inline-formula> denote the number of detectable adenomas arising out of the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e260" xlink:type="simple"/></inline-formula>th ‘special’ <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e261" xlink:type="simple"/></inline-formula>-mutation with sizes <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e262" xlink:type="simple"/></inline-formula>. Clearly, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e263" xlink:type="simple"/></inline-formula>. Then, given <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e264" xlink:type="simple"/></inline-formula>, the events <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e265" xlink:type="simple"/></inline-formula>, for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e266" xlink:type="simple"/></inline-formula>, are independent and identically distributed with<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e267" xlink:type="simple"/><label>(26)</label></disp-formula>Therefore, the joint probability of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e268" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e269" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e270" xlink:type="simple"/></inline-formula>, is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e271" xlink:type="simple"/><label>(27)</label></disp-formula></p>
          <p>In order to derive the joint distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e272" xlink:type="simple"/></inline-formula>, using (27), let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e273" xlink:type="simple"/></inline-formula> denote the set of labels for the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e274" xlink:type="simple"/></inline-formula> clones. Then, summing over all possible <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e275" xlink:type="simple"/></inline-formula> and the possible partitions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e276" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e277" xlink:type="simple"/></inline-formula> subsets, the likelihood is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e278" xlink:type="simple"/></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e279" xlink:type="simple"/></inline-formula> are disjoint subsets of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e280" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e281" xlink:type="simple"/></inline-formula>, and the second sum is over all such <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e282" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e283" xlink:type="simple"/></inline-formula>, the number of labels in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e284" xlink:type="simple"/></inline-formula>. If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e285" xlink:type="simple"/></inline-formula> is not very large, this sum is not difficult to work with.</p>
        </sec>
        <sec id="s2c4">
          <title>Extension to observations in individuals with no prior CRC</title>
          <p>Analogous results can be obtained for observations in individuals who have not developed clinical CRC by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e286" xlink:type="simple"/></inline-formula> by directly conditioning the Poisson rates and using conditional size distributions for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e287" xlink:type="simple"/></inline-formula>. For example, the relevant joint distribution of adenoma number and sizes (i.e., (27)) can be obtained by the following substitutions:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e288" xlink:type="simple"/></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e289" xlink:type="simple"/></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e290" xlink:type="simple"/></disp-formula>and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e291" xlink:type="simple"/></inline-formula> is replaced by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e292" xlink:type="simple"/></disp-formula>Note, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e293" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e294" xlink:type="simple"/></inline-formula> represent the respective probabilities that a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e295" xlink:type="simple"/></inline-formula>-cell born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e296" xlink:type="simple"/></inline-formula> and a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e297" xlink:type="simple"/></inline-formula>-cell born at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e298" xlink:type="simple"/></inline-formula> do not give rise to CRC by time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e299" xlink:type="simple"/></inline-formula>. In other words, they are the tumor survival functions of a 3-stage and 2-stage carcinogenesis model, respectively. For constant parameters, these survival functions are as following (see <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref> for the derivation):<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e300" xlink:type="simple"/><label>(28)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e301" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e302" xlink:type="simple"/></inline-formula> are defined in (4) and (5) with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e303" xlink:type="simple"/></inline-formula> (see <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref> for details). Thus, the conditional expression for adenoma prevalence is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e304" xlink:type="simple"/><label>(29)</label></disp-formula></p>
          <p>The expected number of detectable adenomas conditioned on no prior CRC can be obtained through analogous replacements in (22).</p>
        </sec>
        <sec id="s2c5">
          <title>Detection probability and size distribution for adenomas in individuals with no prior CRC</title>
          <p>As before for the case with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e305" xlink:type="simple"/></inline-formula>, we also provide analogous expressions for the detection probability (23) and size distribution (24), but properly conditioned on no previous occurrence of CRC. The probability of detecting an adenoma at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e306" xlink:type="simple"/></inline-formula> with size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e307" xlink:type="simple"/></inline-formula>, becomes<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e308" xlink:type="simple"/><label>(30)</label></disp-formula>and for the size distribution of detectable adenomas (i.e., their sizes exceeding the threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e309" xlink:type="simple"/></inline-formula>) at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e310" xlink:type="simple"/></inline-formula>, conditioned on no prior CRC, we have<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e311" xlink:type="simple"/><label>(31)</label></disp-formula></p>
        </sec>
      </sec>
      <sec id="s2d">
        <title>Number and Size Distribution for General <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e312" xlink:type="simple"/></inline-formula></title>
        <p>The notation introduced in the previous section is easily generalized to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e313" xlink:type="simple"/></inline-formula>. The random variable <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e314" xlink:type="simple"/></inline-formula> denotes the size of the adenoma at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e315" xlink:type="simple"/></inline-formula> with the corresponding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e316" xlink:type="simple"/></inline-formula>-, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e317" xlink:type="simple"/></inline-formula>,<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e318" xlink:type="simple"/></inline-formula>-mutation times <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e319" xlink:type="simple"/></inline-formula>, respectively. The distribution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e320" xlink:type="simple"/></inline-formula> is, as before, given by the GLD distribution with time origin at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e321" xlink:type="simple"/></inline-formula> and with initiation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e322" xlink:type="simple"/></inline-formula>. Initiated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e323" xlink:type="simple"/></inline-formula>-cells divide or die with rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e324" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e325" xlink:type="simple"/></inline-formula>, respectively. Importantly, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e326" xlink:type="simple"/></inline-formula> depends on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e327" xlink:type="simple"/></inline-formula> alone (i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e328" xlink:type="simple"/></inline-formula>), and the distribution is given by (1) for constant parameters.</p>
        <p>Various combinations of AD-type and PP-type generations for the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e329" xlink:type="simple"/></inline-formula> pre-initiations are possible, but the formulation of the likelihood becomes more complicated. The special cases when all pre-initiations are of PP-type or AD-type are covered in the online supplement (<xref ref-type="supplementary-material" rid="pcbi.1002213.s001">Text S1</xref>).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <p>The derived expressions allow us to readily predict both observable and unobservable numbers of pre-malignant tumors in a tissue. Such predictions are helpful in validating cancer models using intermediate endpoints on precursor lesions, in particular their number and sizes. Furthermore, being able to predict the unobserved portion of precursor lesions is of clinical relevance for early detection and cancer prevention. Here, we illustrate the utility of the derived expressions using the example of colonic adenomas. Specifically, we present the predicted size distribution of adenomas and the age-specific adenoma prevalence, i.e., the probability of finding at least one observable adenoma in an individual as a function of age. Since population-level screening is typically performed on asymptomatic individuals, we also condition on individuals having not developed cancer in the tissue of interest at the time of observation.</p>
      <p>The predictions presented here are for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e330" xlink:type="simple"/></inline-formula> as described above. The underlying CRC model for cancer incidence is the 4-stage model previously derived by Luebeck &amp; Moolgavkar <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref> and updated by Meza et al. <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref>. The alternative model (PP for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e331" xlink:type="simple"/></inline-formula>- and AD for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e332" xlink:type="simple"/></inline-formula>-mutation for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e333" xlink:type="simple"/></inline-formula> in the online supplement (<xref ref-type="supplementary-material" rid="pcbi.1002213.s001">Text S1</xref>)) yields very similar results (not shown). Importantly, not all biological parameters of the MSCE/CRC model are estimable from incidence data alone. For example, for the 4-stage model used here, only the parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e334" xlink:type="simple"/></inline-formula>, the product (slope parameter) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e335" xlink:type="simple"/></inline-formula>, and the ratio <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e336" xlink:type="simple"/></inline-formula> are identifiable. However, if the cell division rate of initiated cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e337" xlink:type="simple"/></inline-formula>, is known, all parameters of the model can be determined (assuming that the number of normal tissue stem cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e338" xlink:type="simple"/></inline-formula>, is known and that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e339" xlink:type="simple"/></inline-formula>). For our illustrations, we choose plausible values for the cell division rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e340" xlink:type="simple"/></inline-formula>, but keep the values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e341" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e342" xlink:type="simple"/></inline-formula> as estimated by Meza et al. <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref>. This affords explicit computation of the adenoma number and size distribution without altering the fits of the model to the observed CRC incidence.</p>
      <p><xref ref-type="fig" rid="pcbi-1002213-g002">Figure 2</xref> (left panel) shows the predicted size distribution of non-extinct adenoma without an imposed detection threshold (i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e343" xlink:type="simple"/></inline-formula>) for the model with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e344" xlink:type="simple"/></inline-formula>. With constant parameters, both the unconditional and conditional (on no prior CRC development) size distributions of detectable adenoma are given by expressions (24) and (31), respectively.</p>
      <fig id="pcbi-1002213-g002" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1002213.g002</object-id>
        <label>Figure 2</label>
        <caption>
          <title>Size distribution of a detectable adenoma and probability of detection of an adenoma.</title>
          <p>Left panel: predicted unconditional (solid) and conditional (dashed) size distribution of a detectable adenoma at age 70 using the parameter estimates obtained by <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref> for females in SEER with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e345" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e346" xlink:type="simple"/></inline-formula>. The cell division rate of initiated cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e347" xlink:type="simple"/></inline-formula>, is assumed as either 9 or 90/year. Right panel: the probability of detection of an adenoma at age 70 as a function of the detection threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e348" xlink:type="simple"/></inline-formula>. Otherwise same as left panel.</p>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.g002" xlink:type="simple"/>
      </fig>
      <p>For sizes sufficiently large, the unconditional adenoma size distribution is roughly log-log-linear, while the conditional size distribution shows departures from this behavior for sizes above <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e349" xlink:type="simple"/></inline-formula> cells, i.e., when the risk of an adenoma-to-carcinoma transition increases more rapidly. This phenomenon is more noticeable when the cell division rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e350" xlink:type="simple"/></inline-formula> is lower. <xref ref-type="fig" rid="pcbi-1002213-g002">Figure 2</xref> (right panel) shows the probability of detecting an adenoma at age 70 as a function of the detection threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e351" xlink:type="simple"/></inline-formula> for both unconditional (solid) and conditional (dashed) adenoma size distributions. Higher cell division rates (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e352" xlink:type="simple"/></inline-formula>) give rise to larger adenoma sizes and hence lead to higher detection probabilities even though the net cell proliferation rate (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e353" xlink:type="simple"/></inline-formula>) is approximately the same. For constant parameters, the unconditional and conditional detection probabilities are given by (23) and (30), respectively. This figure reveals that even for relatively small (i.e., sensitive) thresholds of a few thousand cells, many adenomas may go undetected. However, the precise proportion of detectable adenomas depends on the cell division rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e354" xlink:type="simple"/></inline-formula> with higher values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e355" xlink:type="simple"/></inline-formula> making detection more likely.</p>
      <p><xref ref-type="fig" rid="pcbi-1002213-g003">Figure 3</xref> shows the predicted age-specific adenoma prevalence in asymptomatic individuals for both males and females and for the models with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e356" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e357" xlink:type="simple"/></inline-formula>, as described by Meza et al. <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref>, including their dependence on the observation threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e358" xlink:type="simple"/></inline-formula>. The prevalence is defined as the probability of at least one detectable adenoma at age <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e359" xlink:type="simple"/></inline-formula>, and is given by (11) for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e360" xlink:type="simple"/></inline-formula> and (29) for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e361" xlink:type="simple"/></inline-formula>. In comparison with careful observations from autopsy studies <xref ref-type="bibr" rid="pcbi.1002213-Clark1">[16]</xref>, the model under-estimates these empirical data (represented by filled circles) unless one accepts a very small number of initiated stem cells to be observable. There are several explanations why the model-generated expected prevalence of adenoma might be lower than the clinical data would indicate (see the end of <xref ref-type="sec" rid="s4">Discussion</xref>).</p>
      <fig id="pcbi-1002213-g003" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1002213.g003</object-id>
        <label>Figure 3</label>
        <caption>
          <title>Adenoma prevalence.</title>
          <p>Predicted adenoma prevalence for both males (Left panel) and females (Right panel) as a function of age and various observation thresholds <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e362" xlink:type="simple"/></inline-formula> using the models with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e363" xlink:type="simple"/></inline-formula> (solid lines) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e364" xlink:type="simple"/></inline-formula> (dashed lines). Empirical data from Clark et al. <xref ref-type="bibr" rid="pcbi.1002213-Clark1">[16]</xref> in filled circles.</p>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.g003" xlink:type="simple"/>
      </fig>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>We have previously derived number and size distributions of pre-malignant clones in the context of the two-stage clonal expansion (TSCE) model of carcinogenesis <xref ref-type="bibr" rid="pcbi.1002213-Dewanji1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Luebeck4">[17]</xref> and more recently established a formal connection of these results with fluctuation analyses based on the Luria-Delbrück distribution <xref ref-type="bibr" rid="pcbi.1002213-Dewanji2">[14]</xref>. The mathematical tools derived in these papers were subsequently applied to the problem of screening for colorectal adenoma allowing for interventions resulting from their complete or incomplete removal <xref ref-type="bibr" rid="pcbi.1002213-Jeon1">[6]</xref>. These explorations, however, required time consuming computer simulations. In contrast, here we derive mathematical expressions that allow us to readily compute adenoma number and size distributions without simulation. These expressions can form the basis for computing the likelihood of adenoma data from screening studies involving sigmoidoscopies, colonoscopies and computed-tomographic colonographies, and thus are of significantly practical importance. Moreover the analytical form of the likelihood function allows for parameter estimation and likelihood-based hypothesis testing. Analyses of such data will be forthcoming and are the subject of a separate paper.</p>
      <p>Our previous analyses of CRC incidence data suggest that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e365" xlink:type="simple"/></inline-formula>, the number of requisite pre-initiation mutations, is indeed small <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e366" xlink:type="simple"/></inline-formula> corresponds to a ‘two-hit’ model for initiation, in essence representing the biallelic inactivation of a tumor suppressor gene (Knudson's recessive oncogenesis) <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref>. A model with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e367" xlink:type="simple"/></inline-formula> may describe both the inactivation of a tumor suppressor gene as well as the activation of an oncogene <xref ref-type="bibr" rid="pcbi.1002213-Meza2">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Luebeck3">[12]</xref>. Here, we also treat the case of general <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e368" xlink:type="simple"/></inline-formula>, which can be viewed as a model for clonal evolution due to the tree-structure where the nodes represent immortal mutant stem cells that will give rise to specific sub-clones which may or may not be identified as such. We distinguish between two types of rate-limiting events, one that generates (potentially multiple) mutations via asymmetric cell division while preserving the progenitor stem cell from which the mutations arose (PP-type), and one that leads to a transition of a progenitor cell into one cell that acquires a new mutation (AD-type). The MSCE model used here assumes that all events that lead to initiated cells are PP-type. This is only a mild restriction since for rare events the PP-type emission is equivalent to a AD-type transition (see <xref ref-type="fig" rid="pcbi-1002213-g001">Figure 1</xref>). For frequent (high rate) events, the AD-type transition looses its rate-limiting nature and can be ignored, while the high rate (PP-type) process leads to the accumulation of multiple clones and thus has the potential to capture non-mutational events, such as the transient amplification of proliferative cells from resident stem cells in the colonic crypts. Once a stem cell is considered initiated, i.e., is of type <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e369" xlink:type="simple"/></inline-formula>, we assume that it undergoes a stochastic birth-death process. This leads to the GLD distribution introduced in <xref ref-type="bibr" rid="pcbi.1002213-Dewanji2">[14]</xref> for the adenoma size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e370" xlink:type="simple"/></inline-formula>, which reduces to a Negative Binomial distribution for constant parameters. Note, however, our formalism is more general and can accommodate other growth models that do not result in a GLD size distribution for the initiated cell population emerging from a <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e371" xlink:type="simple"/></inline-formula> progenitor cell <xref ref-type="bibr" rid="pcbi.1002213-Luebeck4">[17]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Tan1">[18]</xref>.</p>
      <p>Finally, we wish to comment on the predictions of the model for the age-specific adenoma prevalence (<xref ref-type="fig" rid="pcbi-1002213-g003">Figure 3</xref>). In comparison with the empirical data, our predictions appear too low. However, the discrepancy depends on what is assumed for the initiated stem cell division rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e372" xlink:type="simple"/></inline-formula> and the detection threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e373" xlink:type="simple"/></inline-formula>. While the range of plausible values for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e374" xlink:type="simple"/></inline-formula> is limited by how fast initiated stem cell can cycle in the adenoma (unlikely more than 2–3 times a week), it is not clear what fraction of cells in an adenoma is truly at risk for malignant transformation <xref ref-type="bibr" rid="pcbi.1002213-Barker1">[10]</xref>. Assuming that a 1 mm adenoma, the caliper size detection limit cited by Clark et al. <xref ref-type="bibr" rid="pcbi.1002213-Clark1">[16]</xref>, contains about 500,000 cells <xref ref-type="bibr" rid="pcbi.1002213-Pinsky1">[19]</xref> and that only 1–10% of cells in an adenoma are tumor stem cells <xref ref-type="bibr" rid="pcbi.1002213-Barker1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Boman1">[20]</xref>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e375" xlink:type="simple"/></inline-formula> may be as low as 5000 cells and therefore the discrepancy may be less dramatic. Alternatively, one might include pre-initiated cells in the adenoma size count. However, our assumption is that pre-initiated cells do not expand clonally, although they may increase in number as a result of multiple births of the same type of mutation from a single stem cell over time (via Poisson process emissions). Thus, since locus-specific mutations are rare (of the order of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e376" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002213.e377" xlink:type="simple"/></inline-formula> per year), the contribution of pre-initiated cells to the overall number of cells in an adenoma is likely very small.</p>
      <p>It is well-recognized that adenomas can be genetically diverse and differ widely in their neoplastic potential. Indeed, adenomas have been suggested to regress implying that there are adenomas that are not on the pathway to cancer <xref ref-type="bibr" rid="pcbi.1002213-Loeve1">[21]</xref>, although regression may simply reflect the stochastic nature of tumor growth. A more intriguing possibility of resolving the discrepancy is that adenomas go through a growth-bottleneck (i.e., stagnancy) before they can become cancerous. In this scenario, adenomas might sojourn in a reservoir until an activating mutation or change in tumor microenvironment releases them from arrest <xref ref-type="bibr" rid="pcbi.1002213-Hahnfeldt1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1002213-Enderling1">[23]</xref>. Although incorporating this scenario into the MSCE model may be challenging, the framework presented here is independent of the particular dynamics of the initiated cells and the number of clonal expansions assumed.</p>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pcbi.1002213.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002213.s001" xlink:type="simple">
        <label>Text S1</label>
        <caption>
          <p>Supplementary methods and results. A tabular glossary which summarizes our notation and succinctly defines the model parameters and terminology in use.</p>
          <p>(PDF)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank our colleagues Dr. Hazelton and Dr. Moolgavkar for helpful discussions.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pcbi.1002213-Winawer1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Winawer</surname><given-names>S</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>R</given-names></name><name name-style="western"><surname>Rex</surname><given-names>D</given-names></name><name name-style="western"><surname>Bond</surname><given-names>J</given-names></name><name name-style="western"><surname>Burt</surname><given-names>R</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Colorectal cancer screening and surveillance: Clinical guidelines and rationaleupdate based on new evidence.</article-title>             <source>Gastroenterology</source>             <volume>124</volume>             <fpage>544</fpage>             <lpage>560</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Jones1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WD</given-names></name><name name-style="western"><surname>Parmigiani</surname><given-names>G</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>F</given-names></name><name name-style="western"><surname>Beerenwinkel</surname><given-names>N</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Comparative lesion sequencing provides insights into tumor evolution.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>4283</fpage>             <lpage>4288</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Luebeck1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name></person-group>             <year>2002</year>             <article-title>Multistage carcinogenesis and the incidence of colorectal cancer.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>99</volume>             <fpage>15095</fpage>             <lpage>15100</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Meza1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Meza</surname><given-names>R</given-names></name><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name></person-group>             <year>2005</year>             <article-title>Gestational mutations and carcinogenesis.</article-title>             <source>Math Biosci</source>             <volume>197</volume>             <fpage>188</fpage>             <lpage>210</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Luebeck2">
        <label>5</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name></person-group>             <year>2006</year>             <article-title>Multistage carcinogenesis: From intestinal stem cell to colon cancer in the population.</article-title>             <person-group person-group-type="editor"><name name-style="western"><surname>Potten</surname><given-names>CS</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>RB</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J</given-names></name><name name-style="western"><surname>Renehan</surname><given-names>AG</given-names></name></person-group>             <source>Tissue stem cells</source>             <publisher-name>Taylor &amp; Francis</publisher-name>             <fpage>215</fpage>             <lpage>228</lpage>             <comment>Chapter 10</comment>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Jeon1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Meza</surname><given-names>R</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name></person-group>             <year>2008</year>             <article-title>Evaluation of screening strategies for premalignant lesions using a biomathematical approach.</article-title>             <source>Math Biosci</source>             <volume>213</volume>             <fpage>56</fpage>             <lpage>70</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Meza2">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Meza</surname><given-names>R</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name></person-group>             <year>2008</year>             <article-title>Age-specific incidence of cancer: Phases, transitions, and biological implications.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>16284</fpage>             <lpage>16289</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Meza3">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Meza</surname><given-names>R</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Renehan</surname><given-names>AG</given-names></name><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name></person-group>             <year>2010</year>             <article-title>Colorectal cancer incidence trends in the united states and united kingdom: evidence of right- to left-sided biological gradients with implications for screening.</article-title>             <source>Cancer Res</source>             <volume>70</volume>             <fpage>5419</fpage>             <lpage>5429</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Goss1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Goss</surname><given-names>KH</given-names></name><name name-style="western"><surname>Groden</surname><given-names>J</given-names></name></person-group>             <year>2000</year>             <article-title>Biology of the adenomatous polyposis coli tumor suppressor.</article-title>             <source>J Clin Oncol</source>             <volume>18</volume>             <fpage>1967</fpage>             <lpage>1979</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Barker1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>N</given-names></name><name name-style="western"><surname>Ridgway</surname><given-names>RA</given-names></name><name name-style="western"><surname>van Es</surname><given-names>JH</given-names></name><name name-style="western"><surname>van de Wetering</surname><given-names>M</given-names></name><name name-style="western"><surname>Begthel</surname><given-names>H</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Crypt stem cells as the cells-of-origin of intestinal cancer.</article-title>             <source>Nature</source>             <volume>457</volume>             <fpage>608</fpage>             <lpage>611</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Potten1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Potten</surname><given-names>CS</given-names></name></person-group>             <year>1998</year>             <article-title>Stem cells in gastrointestinal epithelium: numbers, characteristics and death.</article-title>             <source>Philos Trans R Soc Lond B Biol Sci</source>             <volume>353</volume>             <fpage>821</fpage>             <lpage>830</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Luebeck3">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name></person-group>             <year>2002</year>             <article-title>Multistage carcinogenesis and the incidence of colorectal cancer.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>99</volume>             <fpage>15095</fpage>             <lpage>15100</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Dewanji1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dewanji</surname><given-names>A</given-names></name><name name-style="western"><surname>Venzon</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name></person-group>             <year>1989</year>             <article-title>A stochastic two-stage model for cancer risk assessment. ii. the number and size of premalignant clones.</article-title>             <source>Risk Anal</source>             <volume>9</volume>             <fpage>179</fpage>             <lpage>187</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Dewanji2">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dewanji</surname><given-names>A</given-names></name><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name></person-group>             <year>2005</year>             <article-title>A generalized luriadelbrck model.</article-title>             <source>Math Biosci</source>             <volume>197</volume>             <fpage>140</fpage>             <lpage>152</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Armitage1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Armitage</surname><given-names>P</given-names></name><name name-style="western"><surname>Doll</surname><given-names>R</given-names></name></person-group>             <year>1954</year>             <article-title>The age distribution of cancer and a multi-stage theory of carcinogenesis.</article-title>             <source>Br J Cancer</source>             <volume>8</volume>             <fpage>1</fpage>             <lpage>12</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Clark1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>JC</given-names></name><name name-style="western"><surname>Collan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eide</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Estve</surname><given-names>J</given-names></name><name name-style="western"><surname>Ewen</surname><given-names>S</given-names></name><etal/></person-group>             <year>1985</year>             <article-title>Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer.</article-title>             <source>Int J Cancer</source>             <volume>36</volume>             <fpage>179</fpage>             <lpage>186</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Luebeck4">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Luebeck</surname><given-names>EG</given-names></name><name name-style="western"><surname>Moolgavkar</surname><given-names>SH</given-names></name></person-group>             <year>1991</year>             <article-title>Stochastic analysis of intermediate lesions in carcinogenesis experiments.</article-title>             <source>Risk Anal</source>             <volume>11</volume>             <fpage>149</fpage>             <lpage>157</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Tan1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>WY</given-names></name></person-group>             <year>1986</year>             <article-title>A stochastic gompertz birth-death process.</article-title>             <source>Stat Probabil Lett</source>             <volume>4</volume>             <fpage>25</fpage>             <lpage>28</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Pinsky1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pinsky</surname><given-names>PF</given-names></name></person-group>             <year>2000</year>             <article-title>A multi-stage model of adenoma development.</article-title>             <source>J Theor Biol</source>             <volume>207</volume>             <fpage>129</fpage>             <lpage>143</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Boman1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Boman</surname><given-names>BM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E</given-names></name></person-group>             <year>2008</year>             <article-title>Human colon cancer stem cells: A new paradigm in gastrointestinal oncology.</article-title>             <source>J Clin Oncol</source>             <volume>26</volume>             <fpage>2828</fpage>             <lpage>2838</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Loeve1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Loeve</surname><given-names>F</given-names></name><name name-style="western"><surname>Boer</surname><given-names>R</given-names></name><name name-style="western"><surname>Zauber</surname><given-names>AG</given-names></name><name name-style="western"><surname>Van Ballegooijen</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Oortmarssen</surname><given-names>GJ</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>National Polyp Study data: evidence for regression of adenomas.</article-title>             <source>Int J Cancer</source>             <volume>111</volume>             <fpage>633</fpage>             <lpage>639</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Hahnfeldt1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hahnfeldt</surname><given-names>P</given-names></name><name name-style="western"><surname>Panigrahy</surname><given-names>D</given-names></name><name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name><name name-style="western"><surname>Hlatky</surname><given-names>L</given-names></name></person-group>             <year>1999</year>             <article-title>Tumor development under angiogenic signaling.</article-title>             <source>Cancer Res</source>             <volume>59</volume>             <fpage>4770</fpage>             <lpage>4775</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002213-Enderling1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Enderling</surname><given-names>H</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AR</given-names></name><name name-style="western"><surname>Chaplain</surname><given-names>MA</given-names></name><name name-style="western"><surname>Beheshti</surname><given-names>A</given-names></name><name name-style="western"><surname>Hlatky</surname><given-names>L</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics.</article-title>             <source>Cancer res</source>             <volume>69</volume>             <fpage>8814</fpage>             <lpage>8821</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>